Product Description
AD-E6E7 is being developed by Turnstone Biologics for the treatment of patients with HPV-Associated Cancers. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03618953?term=AD-E6E7&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Turnstone Biologics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Cervical Cancer|Papilloma|Oropharyngeal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Kingfisher | P1 |
Terminated |
Papilloma|Cervical Cancer|Oropharyngeal Cancer |
2021-03-05 |